Cistanche Total Glycosides (CTG)

First Published on Clinicaltrials.gov: 9/15/2008
Status: Currently Recruiting
ClinicalTrials.gov ID: NCT00753571
Sponsor: Peking University
Purpose: This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating patients with amyotrophic lateral sclerosis (ALS).
Phase: II
Treatment Type: Orally available in pill form
Trial Type: Double Blind, Placebo Control
Estimated Enrollment: 40
Eligibility: 18 to 65 years. Both Genders. No healthy volunteers.
Details: Two arm study: active comparator of 1.8g/day (6 capsules) of CTG for 9 months, placebo comparator 6 capsules for 9 months.
Collaborator(s):
Location(s):
  • Beijing, China
Primary Investigator: Dongsheng Fan MD
Contact:
Trial Protocol as Published on Clinicaltrials.gov:
ClinicalTrials.gov   Download PDF
ALS Forum: